Zhou Wenhao, He Ping, Li Junhua, Liu Huan, Shi Mengjuan, Yu Junping, Wei Hongping
CAS Key Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.
University of Chinese Academy of Sciences, Beijing 100049, China.
Viruses. 2022 Feb 7;14(2):335. doi: 10.3390/v14020335.
A new SARS-CoV-2 variant B.1.1.529 was named by the WHO as Omicron and classified as a Variant of Concern (VOC) on 26 November 2021. Because this variant has more than 50 mutations, including 30 mutations on the spike, it has generated a lot of concerns on the potential impacts of the VOC on COVID-19. Here through ELISA assays using the recombinant RBD proteins with sequences the same to that of SARS-CoV-2 WIV04 (lineage B.1), the Delta variant and the Omicron variant as the coating antigens, the binding capabilities between the RBDs and the antibodies in COVID-19 convalescent sera and vaccine sera after two doses of the inactivated vaccine produced by Sinopharm WIBP are compared with each other. The results showed that the Omicron variant may evade antibodies induced by the ancestral strain and by the inactivated vaccine, with significant reduction in the binding capability of its RBD much greater than that of the Delta variant.
一种新型的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株B.1.1.529被世界卫生组织命名为奥密克戎，并于2021年11月26日被列为值得关注的变异株（VOC）。由于该变异株有50多个突变，其中包括刺突蛋白上的30个突变，它引发了人们对该变异株对新冠病毒病（COVID-19）潜在影响的诸多担忧。在此，通过酶联免疫吸附测定（ELISA）试验，使用与SARS-CoV-2 WIV04（B.1谱系）、德尔塔变异株和奥密克戎变异株序列相同的重组受体结合域（RBD）蛋白作为包被抗原，比较了RBD与国药集团中国生物北京生物制品研究所生产的两剂灭活疫苗接种后的COVID-19康复期血清和疫苗血清中抗体之间的结合能力。结果显示，奥密克戎变异株可能逃避由原始毒株和灭活疫苗诱导产生的抗体，其RBD的结合能力显著降低，且降幅远大于德尔塔变异株。
